DK2382990T3 - Fremgangsmåder til behandling af kræft ved anvendelse af et immunotoksin - Google Patents

Fremgangsmåder til behandling af kræft ved anvendelse af et immunotoksin Download PDF

Info

Publication number
DK2382990T3
DK2382990T3 DK10011667.2T DK10011667T DK2382990T3 DK 2382990 T3 DK2382990 T3 DK 2382990T3 DK 10011667 T DK10011667 T DK 10011667T DK 2382990 T3 DK2382990 T3 DK 2382990T3
Authority
DK
Denmark
Prior art keywords
immunotoxin
antibody
cancer
treatment
tumor
Prior art date
Application number
DK10011667.2T
Other languages
English (en)
Inventor
Uwe Zangenmeister-Wittke
Paolo Claudio Di
Dominique Christine Tschudi
Nicholas Ronald Glover
Dimitri Peter Fitsialos
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of DK2382990T3 publication Critical patent/DK2382990T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

1. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af blærekræft ved indgivelse intratumoralt, intravesikulært eller peritu-moralt direkte til kræftstedet, og hvori immunotoksinet omfatter: (a) et antistof eller antistoffragment, som binder til Ep-CAM på den tilknyttede kræftcelle; (b) et toksin, som er cytotoksisk for kræftcellen.
2. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af blærekræft ifølge krav 1, hvori antistoffet eller antistoffragmentet er murint, humaniseret eller et kimærisk antistof eller antistoffragment.
3. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af blærekræft ifølge krav 1 eller 2, hvori antistoffet eller antistoffragmentet er et humaniseret antistof eller antistoffragment.
4. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af blærekræft ifølge krav 3, hvori antistoffet eller antistoffragmentet omfatter komplementaritetsbestemmende region (CDR)-sekvenser som vist i SEQ ID NO:4-9.
5. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af blærekræft ifølge ethvert af krav 1 til 4, hvori antistoffragmentet er et Fab; Fab', (Fab')2, scFv eller dsFv fragment, hvori antistoffragmentet valgfrit er et scFv fragment; hvori antistoffragmentet valgfrit har sekvensen vist i SEQ ID NO:3 eller en variant deraf, eller hvori antistoffet eller fragmentet binder til human Ep-CAM med en dissocieringskonstant (KD) mindre end 2,0 x 10 8.
6. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af blærekræft ifølge ethvert af krav 1 til 5, hvori immunotoksinet har sekvensen vist i SEQ ID NO:2 eller en variant deraf.
7. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af blærekræft ifølge to ethvert af krav 1 til 5, hvori toksinet omfatter en antimetabolit, et middel til opbrydning af DNA, et middel til opbrydning af tubulin, et alkyleringsmiddel, et antimitotisk middel, en topoisomerase l-hæmmer, en topoisomerase Il-hæmmer, en RNA eller DNA antimetabolit, eller vinblastinsulfat eller hvori toksinet er et ribosom-inaktiverende polypeptid; hvori toksinet valgfrit er fra gruppen bestående af gelonin, bouganin, saporin, ricin, ricin A-kæde, bryo-din, difteri og restrictocin, eller hvori toksinet er Pseudomonas exotoksin A eller en variant deraf.
8. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller fore byggelse af blærekræft ifølge ethvert af krav 1 til 5, yderligere omfattende anvendelse af en eller flere kræftterapier til samtidig, separat eller sekventiel behandling eller forebyggelse af blærekræft, hvori kræftterapien omfatter et alkyle-ringsmiddel, et antimitotisk middel, en cytokin, en nervevækstfaktor, en blodpla-deafledt vækstfaktor, hormonterapi, midler, der øger eksprimering af Ep-CAM, stråling, operation, genterapi, vincaalkyloid, et anthracyklin, et antibiotika, et antihistaminmiddel og/eller et middel mod kvalme; hvori kræftterapien valgfrit omfatter Bacillus og Guerin (BCG), bleomycin, carboplatin, cisplatin, docetaxel, flurouracil, cyclofosfamid, cytarabin, irinotecan, gemcitabin, hydroxyurea, interferon, lymfokin, tumornekrosefaktorer, tumornekrosefaktorlignende cytokin, lymfo-toksin, makrofaginflammatorisk protein, granulocyt-monocyt- kolonistimuleringsfaktor, interleukin, methotrexat, mitomycin, oxaliplatin, pacli-taxel, gemtuzumab, rituximab, alemtuzumab, trastuzutmaban, flutamid, tamoxifen, leuprolidacetat, dexamethason, retinoid, betamethason, kortisol, kortison, prednison, dehydrotestosteron, glucocorticoid, mineralocorticoid, østrogen, testosteron, progestin, vinorelbintartrat, 6-mercaptopurin, 6-thioguanin, 5-fluorouracil, fludarabin, dacarbazin, temozoamid, hexametylmelamin, nukleosidanalogier, camptothecin, topotecan eller vineristin.
9. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af blærekræft ifølge ethvert af krav 1 til 8, hvori immunotoksinet gives i en dosis fra ca. 10 til ca. 3000 pg immunotoksin/tumor/dag eller i en dosis fra ca. 20 til ca. 1240 pg immunotoksin/tumor/dag.
10. Effektiv mængde af et immunotoksin til anvendelse ved behandling eller forebyggelse af blærekræft ifølge krav 9, hvori immunotoksinet gives i en cyklus bestående af en daglig dosis i 1 til 7 dage; hvori medikamentet eller immunotoksinet valgfrit gives i 1-6 cyklusser.
11. Kit til anvendelse ved behandling eller forebyggelse af blærekræft omfattende en effektiv mængde af et immunotoksin omfattende (a) et antistof eller antistoffragment, som binder til Ep-CAM på den tilknyttede kræftcelle; (b) et toksin, som er cytotoksisk for kræftcellen.
12. Kit til anvendelse ved behandling eller forebyggelse af blærekræft ifølge krav 11, hvori antistoffet eller antistoffragmentet er murint, humaniseret eller kimæ-risk.
13. Kit til anvendelse ved behandling eller forebyggelse af blærekræft ifølge krav 11 eller 12, hvori liganden er et humaniseret antistof eller antistoffragment omfatter komplementaritetsbestemmende region (CDR)-sekvenser vist i SEQ ID NO:4-9.
14. Kit til anvendelse ved behandling eller forebyggelse af blærekræft ifølge ethvert af krav 11 til 13, hvori antistoffragmentet er et Fab; Fab', (Fab')2, scFv eller dsFv fragment, hvori antistoffragmentet valgfrit er et scFv fragment; hvori antistoffragmentet valgfrit har sekvensen vist i SEQ ID NO:3 eller en variant deraf, eller hvori antistoffet eller fragmentet binder til human Ep-CAM med en dissocie-ringskonstant (KD) mindre end 2,0 x 10'8.
15. Kit til anvendelse ved behandling eller forebyggelse af blærekræft ifølge ethvert af krav 11 til 14, hvori immunotoksinet har sekvensen vist i SEQ ID NO:2 eller en variant deraf.
DK10011667.2T 2003-04-30 2004-04-30 Fremgangsmåder til behandling af kræft ved anvendelse af et immunotoksin DK2382990T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46660803P 2003-04-30 2003-04-30
EP04730425A EP1635868A1 (en) 2003-04-30 2004-04-30 Methods for treating cancer using an immunotoxin

Publications (1)

Publication Number Publication Date
DK2382990T3 true DK2382990T3 (da) 2014-12-15

Family

ID=33418401

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14172801.4T DK2829283T3 (da) 2003-04-30 2004-04-30 Fremgangsmåde til behandling af kræft ved brug af immunotoxin
DK10011667.2T DK2382990T3 (da) 2003-04-30 2004-04-30 Fremgangsmåder til behandling af kræft ved anvendelse af et immunotoksin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14172801.4T DK2829283T3 (da) 2003-04-30 2004-04-30 Fremgangsmåde til behandling af kræft ved brug af immunotoxin

Country Status (13)

Country Link
US (6) US20070196366A1 (da)
EP (3) EP1635868A1 (da)
JP (1) JP4988333B2 (da)
CN (1) CN100417414C (da)
AU (1) AU2004234191A1 (da)
CA (2) CA2826735C (da)
DK (2) DK2829283T3 (da)
ES (2) ES2526219T3 (da)
HU (1) HUE033533T2 (da)
IL (2) IL171643A (da)
PL (2) PL2382990T3 (da)
PT (2) PT2829283T (da)
WO (1) WO2004096271A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171468B1 (en) 1999-04-09 2008-07-02 Universität Zürich Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
PL2382990T3 (pl) 2003-04-30 2015-04-30 Univ Zuerich Sposoby leczenia raka z zastosowaniem immunotoksyny
US20060127399A1 (en) * 2004-09-13 2006-06-15 Defu Zeng Compositions and methods for inducing chimerism in a subject
CA2593648A1 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
CA2597638A1 (en) * 2005-02-16 2006-08-24 University Of Zuerich Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
WO2007071061A1 (en) * 2005-12-23 2007-06-28 Viventia Biotech Inc. Methods for generating and screening fusion protein libraries and uses thereof
WO2008128330A1 (en) * 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
RU2350338C2 (ru) * 2007-05-14 2009-03-27 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ лечения поверхностного рака мочевого пузыря
RU2352340C1 (ru) * 2007-06-27 2009-04-20 Федеральное Государственное Учреждение Ростовский научно-исследовательский онкологический институт Росмедтехнологий Способ химиотерапии при раке мочевого пузыря
CA2700815A1 (en) * 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
US8110193B2 (en) * 2007-12-21 2012-02-07 City Of Hope Methods for conditioning a subject for hematopoietic cell transplantation
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
US20100055107A1 (en) * 2008-07-31 2010-03-04 Defu Zeng Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning
WO2010051635A1 (en) * 2008-11-06 2010-05-14 University Of Guelph Methods of improving the therapeutic efficacy and utility of antibody fragments
BRPI0922789A2 (pt) * 2008-12-05 2019-10-15 Abraxis Bioscience Llc peptídeo de ligação de albumina intermediador para reconhecimento de doença
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2011031441A1 (en) * 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
WO2011032296A1 (en) 2009-09-21 2011-03-24 Mount Sinai Hospital Methods and compositions for the diagnosis and treatment of thyroid cancer
EP2480563B1 (en) 2009-09-24 2017-02-22 The Regents of The University of California Bladder cancer specific ligand peptides
WO2011047135A2 (en) * 2009-10-14 2011-04-21 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treating bladder cancer
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
SG185100A1 (en) 2010-05-04 2012-11-29 Paul Walfish Method for the diagnosis of epithelial cancers by the detection of epicd polypeptide
MX360946B (es) * 2010-09-22 2018-10-29 Amgen Inc Star Inmunoglobulinas portadoras y usos de las mismas.
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
KR20160006697A (ko) * 2013-04-12 2016-01-19 비벤티아 바이오 인코포레이티드 간세포 암종을 검출 및 치료하기 위한 조성물 및 방법
WO2015048901A1 (en) 2013-10-02 2015-04-09 Viventia Bio Inc. Anti-epcam antibodies and methods of use
CN107580501A (zh) * 2015-03-12 2018-01-12 维文蒂亚生物公司 用于靶向epcam阳性膀胱癌的给药策略
CA2979394A1 (en) * 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
CN110430885A (zh) * 2017-03-22 2019-11-08 学校法人兵库医科大学 用于对标准化疗不反应或不耐受且无法根治性切除的进行性或复发性癌患者的治疗的药物
WO2018220467A1 (en) * 2017-05-30 2018-12-06 Foroogh Nejatollahi Anti-muc18 human immunotoxin and applications thereof
JP2020527556A (ja) 2017-07-10 2020-09-10 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ がん治療用ペプチドサポリン複合体
EP3652196A4 (en) 2017-07-10 2021-08-18 Brown, Kathlynn, C. MOLECULAR GUIDANCE SYSTEMPEPTIDES AND USES THEREOF
CN108122613B (zh) * 2018-01-15 2022-04-01 北京颐圣智能科技有限公司 基于健康预测模型的健康预测方法和装置
CN110194803B (zh) * 2019-06-26 2021-01-05 上海科棋药业科技有限公司 一种靶向EpCAM的嵌合抗原受体及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4677070A (en) 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5082927A (en) 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4933288A (en) 1986-11-21 1990-06-12 Cetus Corporation Use of a modified soluble Pseudomonas exotoxin A in immunoconjugates
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5621078A (en) 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
WO1991009949A1 (en) 1990-01-02 1991-07-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Target-specific, cytotoxic, recombinant pseudomonas exotoxin
US5458878A (en) 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
DK0531434T3 (da) 1990-05-11 2000-01-31 Us Health Forbedrede Pseudomonas-exotoksiner med lav dyretoksicitet og høj cytocidal aktivitet
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
WO1993025690A1 (en) 1992-06-18 1993-12-23 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant pseudomonas exotoxin with increased activity
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
WO1997013529A1 (en) 1995-10-13 1997-04-17 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
JP2000511050A (ja) 1996-05-31 2000-08-29 メディジーン・アクチェンゲゼルシャフト 機能性分子表面の生成、スクリーニング、および展開のための新規の合成タンパク質の構造の鋳型
JP2001504334A (ja) 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
CA2295189C (en) 1997-06-06 2010-11-23 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
ES2590912T3 (es) * 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1171468B1 (en) 1999-04-09 2008-07-02 Universität Zürich Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment
GB9911569D0 (en) * 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
US20030148950A1 (en) 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
JP2005507659A (ja) * 2001-10-15 2005-03-24 イミューノメディクス、インコーポレイテッド 直接ターゲッティング結合タンパク質
US20040022726A1 (en) 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
SI21272A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli
CA2424255A1 (en) 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
PL2382990T3 (pl) 2003-04-30 2015-04-30 Univ Zuerich Sposoby leczenia raka z zastosowaniem immunotoksyny
MXPA06010716A (es) 2004-03-19 2007-02-21 Merck Patent Gmbh Proteinas bouganin modificadas, citotoxinas y metodos y usos de las mismas.
EP1766017B1 (en) 2004-06-10 2015-01-21 Viventia Bio Inc. Tumor specific antibody
US20090171317A1 (en) 2006-03-10 2009-07-02 Ebrahim Versi Self-Catheterization Device To Administes Compounds To The Bladder
EP2079840A4 (en) 2006-10-30 2010-06-30 Viventia Biotech Inc IMMUNOTOXIN FUSIONS COMPRISING PROTEASEPLATABLE LINKER-ASSOCIATED ANTIBODY FRAGMENT AND PLANT TOXIN
WO2008128330A1 (en) 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
CA2700815A1 (en) 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
AU2010234335A1 (en) 2009-04-08 2011-10-13 Deutsches Krebsforschungszentrum Amatoxin-armed target-binding moieties for the treatment of cancer
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CN107080847A (zh) 2011-06-24 2017-08-22 森彻斯有限公司 细胞外靶向药物缀合物
KR20160006697A (ko) 2013-04-12 2016-01-19 비벤티아 바이오 인코포레이티드 간세포 암종을 검출 및 치료하기 위한 조성물 및 방법
WO2015048901A1 (en) 2013-10-02 2015-04-09 Viventia Bio Inc. Anti-epcam antibodies and methods of use
CN107580501A (zh) 2015-03-12 2018-01-12 维文蒂亚生物公司 用于靶向epcam阳性膀胱癌的给药策略
WO2017040801A2 (en) 2015-09-02 2017-03-09 Viventia Bio Inc. Methods for making and using an immunoconjugate for the treatment of cancer

Also Published As

Publication number Publication date
EP2382990A1 (en) 2011-11-02
CA2524124C (en) 2014-03-25
CA2826735A1 (en) 2004-11-11
PT2382990E (pt) 2014-12-29
CA2826735C (en) 2019-06-04
PT2829283T (pt) 2017-09-08
US20140178417A1 (en) 2014-06-26
IL213621A0 (en) 2011-07-31
US11713351B2 (en) 2023-08-01
US8545840B2 (en) 2013-10-01
EP1635868A1 (en) 2006-03-22
CN100417414C (zh) 2008-09-10
EP2829283A1 (en) 2015-01-28
WO2004096271A1 (en) 2004-11-11
US20070196366A1 (en) 2007-08-23
IL171643A (en) 2011-08-31
CN1816352A (zh) 2006-08-09
AU2004234191A1 (en) 2004-11-11
US9259484B2 (en) 2016-02-16
DK2829283T3 (da) 2017-09-18
ES2639301T3 (es) 2017-10-26
HUE033533T2 (en) 2017-12-28
IL213621A (en) 2013-12-31
US11713352B2 (en) 2023-08-01
US20210040203A1 (en) 2021-02-11
JP4988333B2 (ja) 2012-08-01
US10858429B2 (en) 2020-12-08
HK1206617A1 (en) 2016-01-15
EP2829283B1 (en) 2017-06-07
PL2382990T3 (pl) 2015-04-30
CA2524124A1 (en) 2004-11-11
US20100249039A1 (en) 2010-09-30
US20160199507A1 (en) 2016-07-14
ES2526219T3 (es) 2015-01-08
US20210317203A1 (en) 2021-10-14
JP2006526576A (ja) 2006-11-24
EP2382990B1 (en) 2014-09-17
PL2829283T3 (pl) 2017-12-29

Similar Documents

Publication Publication Date Title
US11713351B2 (en) Immunotoxin for treating cancer
US20160060352A1 (en) Compositions and methods for detection and treatment of hepatocellular carcinoma
AU2016228760B2 (en) Dosing strategies for targeting EPCAM positive bladder cancer
CN105764925A (zh) 抗EpCAM抗体和使用方法
EP1848462B1 (en) Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9
HK1206617B (en) Methods for treating cancer using an immunotoxin
WO2016187571A2 (en) Her2 immunotoxins and methods of using the same